Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma

Histology and Histopathology

Volumn 22, Issue 1-3, 2007, Pages 107-118

  Petraki, Constantina D ^a,c   Sfikas, C P ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Prostate cancer; Prostate gland; Radiation; Therapy; Total androgen blockade

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BCG VACCINE; CORTICOSTEROID; DUTASTERIDE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

APOPTOSIS; ATROPHY; BENIGN TUMOR; BLADDER CANCER; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CELL DAMAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM CELL; ESTROGEN THERAPY; EXTERNAL BEAM RADIOTHERAPY; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; HYPOTHALAMUS; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; NEEDLE BIOPSY; ORCHIECTOMY; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATECTOMY; PROSTATITIS; RECURRENT CANCER; REVIEW; SUPERFICIAL CANCER;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CHOLESTENONE 5 ALPHA-REDUCTASE; ESTROGENS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 33846293627     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Armas O.A., Aprikian A.G., Melamed J., Cordon-Cardo C., Cohen D.W., Erlandson R., Fair W.R. and Reuter V.E. (1994). Clinical and pathological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am. J. Surg. Pathol. 18, 979-991.
2. Balaji K.C., Rabbani F., Tsai H., Bastar A. and Fair W.R. (1999). Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J. Urol. 162, 753-757.
3. Bazinet M., Zheng W., Begin L.R., Aprikian A.G., Karakiewicz P.I. and Elhilali M.M. (1997). Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49, 721-725.
4. Bocking A. and Auffermann W. (1987). Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system. Diagn. Cytopathol. 3, 108-111.
5. Boni R.A., Sulser T., Jochum W., Romanowski B., Debatin J.F. and Krestin G.P. (1997). Laser ablation-induced changes in the prostate: findings at endorectal MR imaging with histologic correlation. Radiology 202, 232-236.
6. Bono A.V., Pagano F., Montironi R., Zattoni F., Manganelli A., Selvaggi F.P., Comeri G., Fiaccavento G., Guazzieri S., Selli C., Lembo A., Cosciani-Cunico S., Potenzoni D., Muto G., Diamanti L., Santinelli A., Mazzuccelli R., Prayer-Galletti T. and Italian PROSIT Study Group. (2001). Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 57, 117-121.
7. Borkowski P., Robinson M.J., Poppiti R.J. and Nash S.C. (1996). Histologic findings in postcryosurgical prostatic biopsies. Mod. Pathol. 9, 807-811.
8. Bostwick D.G. (1997). Neoplasms of the prostate. In: Urologic surgical pathology. Bostwick D.G. and Eble J.N. (eds). Mosby, St. Louis, Baltimore, Boston. pp 343-421.
9. Bostwick D.G., Egbert B.M. and Fajardo L.F. (1982). Radiation injury of the normal and neoplastic prostate. Am. J. Surg. Pathol. 6, 541-551.
10. Bullock M.J., Srigley J.R., Klotz L.H. and Goldenberg S.L. (2002). Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma. A detailed analysis of radical prostatectomy specimens from a randomized trial. Am. J. Surg. Pathol. 26, 1400-1413.
11. Cheng L., Cheville J. and Bostwick D. (1999). Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am. J. Surg. Pathol. 23, 1173-1183.
12. Civantos F., Marcial M.A., Banks E.R., Ho C.K., Speights V.O., Drew P.A., Murphy W.M. and Soloway M.S. (1995). Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75, 1634-1641.
13. Civantos F., Soloway M.S. and Pinto J.E. (1996). Histopathological effects of androgen deprivation in prostatic cancer. Semin. Urol. Oncol. 14 (2 Suppl), 22-31.
14. Crook J., Robertson S., Collin G., Zaleski V. and Esche B. (1993). Clinical relevance of trans-rectal ultrasound biopsy and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 27, 31-37.
15. Crook J., Robertson S. and Esche B. (1994). Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int J Radiation Oncol. Biol. Phys. 30, 303-308.
16. Crook J., Malone S., Perry G., Bahadur Y., Robertson S. and Abdolell M. (2000). Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Rad. Onc. Biol. Phys. 48, 355-367.
17. Dhom G. and Degro S. (1982). Therapy of prostatic cancer and histopathologic follow-up. Prostate 3, 531-542.
18. Drew P.A., Murphy W.M., Kubilis P.S. and Areford M. (1997). Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? J. Urol. 157, 2201-2205.
19. Dugan T.C., Shipley W.U., Young R.H., Verhey L.Y., Althausen A.F., Heney N.M., McManus P.L. and Abraham E.H. (1991). Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J. Urol. 146, 1313-1316.
20. Ellison E., Bostwic DG., Ferguson J. and Zincke H. (1993). 'Nucleoli poor' clear cell adenocarcinoma of the prostate: a distinctive histologic pattern following total androgen blockade. Mod. Pathol. 6, 59A.
21. English H.F., Kyprianou N. and Isaacs J.T. (1989). Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15, 233-250.
22. Epstein J.I. and Murphy W.M. (1997). Diseases of the prostate gland and seminal vesicles. In: Urological pathology. Murphy W.M. (ed). WB Saunders Company, Philadelphia, London, Toronto, pp 148-241.
23. Epstein J.I. and Yang J.Y. (2002). Prostate biopsy interpretation. Lippincott Williams and Wilkins, Phildelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo.
24. Epstein J.I., Algaba F. and Allsbrook W.C. (2004). Tumours of the prostate. In: Pathology and genetics of tumours of the urinary system and male genital organs. Elbe J.N., Sauter G., Epstein J.I., Sesterhenn I.A. (eds). WHO, IARC Press, Lyon. pp 159-215.
25. Fair W.R., Aprikian A., Sogani P., Reuter V. and Whitmore W.F. (1993). The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71, 1031-1038.
26. Falconieri G., Lugnani F., Zanconati F., Signoretto D. and Di Bonito L. (1996). Histopathology of the frozen prostate. The microscopic bases of prostatic carcinoma cryoablation. Pathol. Res. Pract. 192, 579-587.
27. Ferguson J., Zincke H. and Ellison E. (1994). Decrease of prostatic intraepithelial neoplasia (prostatic intraepithelial neoplasia) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44, 91-95.
28. Foster C. S. and Ke Y. (1998). Prostate cancer - current developments. In: Progress in pathology. Volume 4. Kirkham N. and Lemoine N.R. (eds). Churchill, Livingstone, Edinburgh. pp 137-164.
29. Gardner W.A. and Bennett B.D. (1992). The prostate-overview: recent insights and speculations. In: Pathology and pathobiology of the urinary bladder and prostate. Weinstein R.S. and Gardner W.A. (eds). Williams & Wilkins, Baltimore, Hong Kong, London. pp 129-148.
30. Gomella L.G., Zeltser I. and Valicenti K. (2003). Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 62 (Suppl 6B), 46-54.
31. Grignon D. and Troster M. (1985). Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate 7, 195-202.
32. Grignon D.J. and Sakr W.A. (1995). Histologic effects of radiation therapy and total androgen blockade on prostate cancer. Cancer 75, 1837-1841.
33. Guinan P., Didomenico D., Brown J., Shaw M., Sharifi R., Ray V., Shott S. and Rubenstein M. (1997). The effect of androgen deprivation on malignant and benign prostate tissue. Med. Oncol. 14, 145-152.
34. Hachiya T., Akakura K., Saito S., Shinohara N., Sato K., Harada M., Kato T. and Okada K. (2005). A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. B.J.U. Int. 95, 534-540.
35. Hellstrom M., Ranepall P., Wester K., Brandstedt S. and Busch C. (1997). Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. Br. J. Urol. 79, 421-426.
36. Helpap B. (1985). Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Appl. Pathol. 3, 230-241.
37. Helpap B. (2002). Fundamentals on the pathology of prostatic carcinoma after brachytherapy. World J. Urol. 20, 207-212.
38. Helpap B. and Koch V. (1991). Histological and immunohistochemical findings of prostatic carcinoma after external or interstitial radiotherapy. J. Cancer Res. Clin. Oncol. 117, 608-614.
39. Iczkowski K.A., Qiu J., Qian J., Somerville M.C., Rittmaster R.S., Andriole G.L. and Bostwick D.G. (2005). The dual 5-alpha-reductase inhibitor dutsteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65, 76-82.
40. Irisawa C., Yoshimura Y., Yokota T., Yamaguchi O., Kondou Y., Hamasaki T., Yamad Y., Kurosu S. and Chiba R. (1996). Histological effects of short term endocrine therapy on prostatic cancer. Nippon. Hinyokika. Gakkai. Zasshi. 87, 977-985.
41. Kabalin J.N. (1992). Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J. Urol. 148, 1565-1566 (letter).
42. Khair A.A., Pacelli A., Iczkowski K.A., Cheng L., Corica F.A., Larson T.R., Corica A. and Bostwick D.G. (1999). Does transurethral microwave thermotherapy have a different effect on prostate cancer than on benign or hyperplastic tissue? Urology 54, 67-72.
43. Kiesling V.J., Friedman H.I., McAninch J.W., Nachtsheim D.A. and Nemeth T.J. (1979). The ultrastructural changes of prostatic adenocarcinoma following exernal beam radiation therapy. J. Urol. 122, 633-636.
44. Kitagawa Y., Koshida K., Mizokami A., Komatsu K., Nakashima S., Misaki T., Katsumi T. and Namiki M. (2003) Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int. J. Urol. 10, 377-382.
45. Koppie T.M., Shinohara K., Grossfeld G.D., Presti J.C. and Carroll P.R. (1999). The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J. Urol. 162, 427-432.
46. Kucway R., Vicini F., Huang R., Stromberg J., Gonzalez J. and Martinez A. (2002). Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J. Urol. 167, 2443-2447.
47. Kunzle C.M., Kuhn H., Dvorak O. and Kuhn R. (1997). A comparative histopathological study of the influence of chemo- and radiotherapy on human prostatic carcinoma grown in nude mice. Exp. Toxicol. Pathol. 49, 249-252.
48. Kyprianou N., English H. and Isaacs J.T. (1990). Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50, 3748-3753.
49. Leistenschneider W. and Nagel R. (1983). Cytological monitoring of the therapy of conservatively treated prostate cancer. Classification and clinical significance. Urologe 22, 144-150.
50. Littrup P.J., Mody A., Sparschu R., Prchevski P., Montie J., Zingas A. and Grignon D. (1994). Prostatic cryotherapy: ultrasonographic and pathologic correlation in the canine model. Urology 44, 175-183.
51. Ljung G., Norberg M., Holmberg L., Busch C. and Nilsson S. (1997). Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. Prostate 31, 91-97.
52. Locke J.R., Soloway M.S., Evans J. and Murphy W.M. (1986). Osteogenic differentiation associated with x-ray therapy for adenocarcinoma of the prostate gland. Am. J. Clin. Pathol. 85, 375-378.
53. Lopez Lopez C., Quilez Fenoll J.M., Gomez Ruiz J.J., Lopez Lopez A.F. and Romero Maroto Y.S. (1996). Histologic regression of localized prostatic tumour with neoadjuvant hormonal therapy. Arch. Esp. Urol. 49, 819-823.
54. Magi-Galluzzi C., Montironi R., Giannulis I., Diamanti L., Scarpelli M., Muzzonigro G. and Polito M. (1993). Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol. Res. Pract. 189, 1154-1160.
55. Magi-Galluzzi C., Sanderson H. and Epstein J.I. (2003). Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer. Am. J. Surg. Pathol. 27, 206-212.
56. Mahan D.E., Bruce A.W., Manley P.N. and Franchi L. (1980). Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. J. Urol. 124, 488-492.
57. Mauroy B., Chive M., Stefaniak X., Demetriou D., Prevost B., Hattab B., Sozanski J.P., Carpentier B., Biserte J. and Mazeman E. (1997). Study of the effects of thermotherapy in benign prostatic hypertrophy. Eur. Urol. 32, 198-208.
58. Mazzuccelli R., Montironi R., Santinelli A., Lucarini G., Pugnaloni A. and Biagini G. (2000). Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45, 72-79.
59. Mollenkamp J.S., Cooper J.E. and Kagan A.R. (1975). Clinical experience with supervoltage radiotherapy in carcinoma of the prostate: a preliminary report. J. Urol. 113, 374-377.
60. Montironi R. and Schulman C.C. (1998). Pathological changes in prostate lesions after androgen manipulation. J. Clin. Pathol. 51, 5-12.
61. Montironi R., Valli M. and Fabris G. (1996). Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J. Clin. Pathol. 49, 324-328.
62. Montironi R., Pomante R., Diamanti L. and Magi-Galluzzi C. (1998). Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol. Int. 60 Suppl 1, 25-30.
63. Montironi R., Diamanti L., Santinelli A., Galetti-Prayer T., Zattoni F., Selvaggi F.P., Pagano F. and Bono A.V. (1999). Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. Pathol. Res. Pract. 195, 201-208.
64. Mukamel E., Konichezky M., Engelstein D., Cytron S., Abramovici A. and Servadio C. (1990). Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations. J. Urol. 144, 1399-1400.
65. Murphy W.M., Soloway M.S. and Barrows G.H. (1991). Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68, 821-828.
66. Musselman P.W., Tubbs R. and Connelly R.W. (1987). Biological significance of prostatic carcinoma after definitive radiation therapy. J. Urol. 137, 114A.
67. Nielsen K., Berild G.H., Bruun E., Jorgensen P.E. and Weis N. (1992). The prognostic value of histological grading and mean nuclear volume in human prostatic cancer. Prostate 21, 53-61.
68. Orihuela E., Motamedi M., Pow-Sang M., LaHaye M., Cowan D.F. and Warren M.M. (1995). Histopathological evaluation of laser thermocoagulation in the human prostate: optimization of lazer irradiation for benign prostatic hyperplasia. J. Urol. 153, 1531-1536.
69. Pareck G. and Nakada S.Y. (2005). The current role of cryotherapy for renal and prostate tumors. Urol. Oncol. 23, 361-366.
70. Polito M., Muzzonigro G., Minardi D. and Montironi R. (1996). Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. Eur. Urol. 30 Suppl 1, 26-31.
71. Pomante R., Santinelli A., Muzzonigro G. and Montironi R. (1999). Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride. Anal. Quant. Cytol. Histol. 21, 63-69.
72. Porter A.T. and Forman J.D. (1993). Prostate brachytherapy. An Overview. Cancer 71, 953-958.
73. Rosai J. (2004). Male reproductive system. Prostate and seminal vesicles. In: Rosai and Ackerman's surgical pathology. Rosai J. (ed). Mosby. Edinburgh, London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto. pp 1361-1412.
74. Scardino P.T., Frankel J.N., Wheeler T.M., Meacham R.B., Hoffman G.S., Seale C., Wilbanks J.H., Easley J. and Carlton C.E. (1986). The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J. Urol. 135, 510-516.
75. Schenken J.R., Burns E.L. and Kahle P.J. (1942). The effect of diethylstilbestrol diethylstilbestrol dipropionate on carcinoma of the prostate gland. II. Cytologic changes following treatment. J. Urol. 48, 99-112.
76. Schmeller N.T., Jocham D., Staehler G., Schmied E., Davis J. and Drach G.W. (1986). Cytologic regression grading of hormone-treated prostatic cancer. Prostate 9, 1-7.
77. Schulman C.C., Debruyne F.M., Forster G., Selvaggi F.P., Zlotta A.R. and Witjes W.P. (2000). 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38, 706-713.
78. Scolieri M.J., Altman A. and Resnick M.I. (2000). Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J. Urol. 164, 1465-1472.
79. Shinohara K. (2004). Thermal ablation of prostate diseases: advantages and limitations. Int. J. Hyperthermia 20, 679-697.
80. Siders D.B. and Lee F. (1992). Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum. Pathol. 23, 344-351.
81. Smith D.M. and Murphy W.M. (1994). Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73, 1472-1477.
82. Soloway M.S., Sharifi R., Wajsman Z., McLeod D., Wood, D. and Puras-Baez A. (1995). Randomized prospective study comparing radical prostactectomy alone versus radical prostactectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154, 424-428.
83. Sulser T., Jochum W., Huch Boni R.A., Briner J., Krestin G.P. and Hauri D. (1997). Laser treatment of benign prostatic hypertrophy: the correlation of histologic results to nuclear magnetic resonance imaging. Ann. Urol. (Paris) 31, 19-26.
84. Sun Z.Y., Wu H.Y., Wang M.Y. and Tu Z.K. (1999). The mechanism of episteride against benign prostatic hyperplasia. Eur. J. Pharmacol. 371, 227-233.
85. Suzuki T., Kurokawa K., Suzuki K., Matsumoto K. and Yamanaka H. (1995). Histological and immunohistochemical changes after transurethral balloon laser hyperthermia in the canine prostate. Tohoka. J. Exp. Med. 177, 39-48.
86. Szende B., Romics I., Minik K., Szabo J., Torda I., Lovasz S., Szomor L., Toth L., Bely M., Kerenyi T., Bartok K. and Vegh A. (2001). Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma. Prostate 49, 93-100.
87. Tetu B., Srigley J.R., Boivin J.C., Dupont A., Monfette G., Pinault S. and Labrie F. (1991). Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am. J. Surg. Pathol. 15, 11-120.
88. Tostain J., Versini P., Legon C., Li G., Ludot T., Castro R., Armand C. and Boucheron S. (1997). Anatomical and clinical effects of neoadjuvant hormonal treatment before radical prostatectomy. Prog. Urol. 7, 570-578.
89. Tran T.A., Jennings T.A., Ross J.S. and Nazeer T. (1998). Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am. J. Surg. Pathol. 22, 347-354.
90. Vailancourt L., Tetu B., Fradet Y., Dupont A., Gomez J., Cusan L., Suburu E.R., Diamond P., Candas B. and Labrie F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am. J. Surg. Pathol. 20, 86-93.
91. Van de Voorde W.M., Elgamal A.A., Van Poppel H.P., Verbeken E.K., Baert L.V. and Lauweryns J.M. (1994). Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74, 3164-3175.
92. Van der Kwast T.H., Labrie F. and Tetu B. (1999). Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol. 35, 508-510.
93. Vernon S.E. and Williams W.D. (1983). Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J. Urol. 130, 95-98.
94. Wheeler J.A., Zagars G.K. and Ayala A.G. (1993). Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 71, 3783-3787.
95. Wilkstrom P., Westin P., Stattin P., Damber J.E. and Bergh A. (1999). Early castration-induced upregulation of transforming growth factor beta 1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 38, 268-277.
96. Wozniak A.J., Blumenstein B.A., Crawford E.D., Boileau M., Rivkin S.E. and Fletcher W.S. (1993). Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer 71, 3975-3978.
97. Yang X.J., Lecksell K., Short K., Gottesman J., Peterson L., Bannow J., Schellhammer P.F., Fitch W.P., Hodge G.B., Parra R., Rouse S., Waldstreicher J. and Epstein J.I. (1999). Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 53, 696-700.
98. Young R.H., Srigley J.R., Amin M., Ulbright T.M. and Cubilla A.L. (2000). Tumors of the prostate gland, seminal vesicles, male urethra, and penis. AFIP, Bethesda, Maryland.
99. Zalatnai A., Paz-Bouza J.I., Redding T.W. and Schally A.V. (1988). Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate 12, 85-98.